OR

Browse By

Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52 week study evaluating the safety and efficacy of Simufilam 100mg tablets in subjects with mild-to-moderate Alzheimer's Disease (2023–2025)

Grant type:
Premier Research (Australia) Pty Ltd
Researchers:

  • Dr Rob Adam

    Trials Medical Specialist
    UQ Centre for Clinical Research
    Faculty of Medicine
Funded by:
Premier Research (Australia) Pty Ltd